Pacira BioSciences Inc (NAS:PCRX)
$ 16.81 -0.7 (-4%) Market Cap: 776.17 Mil Enterprise Value: 998.18 Mil PE Ratio: 0 PB Ratio: 1.03 GF Score: 72/100

Q4 2018 Pacira Pharmaceuticals Inc Earnings Call Transcript

Feb 28, 2019 / 01:30PM GMT
Release Date Price: $41.18 (+1.35%)
Operator

Good day, ladies and gentlemen, and welcome to the Q4 2018 Pacira Pharmaceuticals Earnings Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded. I would now like to introduce your host for today's conference, Head of Investor Relations, Susan Mesco. Ms. Mesco, you may begin.

Susan Mesco
Pacira Pharmaceuticals, Inc. - Head of IR

Thank you, Josh, and good morning, everyone. Welcome to today's conference call to discuss our fourth quarter and year-end 2018 financial results. Joining me on today's call are Dave Stack, Chairman and Chief Executive Officer; Dr. Richard Scranton, our Chief Medical Officer; and Charlie Reinhart, our Chief Financial Officer.

Before we start, let me remind you that today's call will include forward-looking statements based on current expectations. Such statements represent our judgment as of today and may involve risks and uncertainties. Please refer to our filings with the SEC, which are available from the SEC or our website for information concerning risk factors that could affect the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot